FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387214663> ?p ?o ?g. }

• W4387214663 abstract "Abstract Background Pimobendan is an important therapy for dogs with myxomatous mitral valve disease (MMVD). The pharmacokinetics are reported in healthy dogs but not in dogs with heart disease. Hypothesis/Objectives To determine if dog characteristics such as age, breed, body condition score, ACVIM stage of heart disease or biochemical laboratory value alter the pharmacokinetics of orally administered pimobendan and its metabolite in a cohort of dogs with naturally occurring MMVD. Animals Fifty‐seven client‐owned dogs with MMVD ACVIM Stage B2, C, or D and administered pimobendan to steady state blood concentrations. Methods Prospective, observational study. Samples were collected using a sparse‐sampling protocol at specific intervals after administration of pimobendan. Plasma pimobendan and the active metabolite (O‐desmethyl‐pimobendan, ODMP) concentrations were determined via high‐pressure liquid chromatography and fluorescence detection. Data was analyzed via a population pharmacokinetic approach and nonlinear mixed effects modeling (NLME). Numerous covariates were examined in the NLME model. Results The absorption and elimination half‐lives ( t 1/2 ) were approximately 1.4 and 1 hour for pimobendan and 1.4 and 1.3 hours for ODMP, respectively. Pharmacokinetic parameters were highly variable, especially the values for pimobendan absorption and elimination rate, and absorption rate of ODMP with coefficients of variation of 147.84%, 64.51% and 64.49%, respectively. No covariate evaluated was a significant source of variability. Conclusions and Clinical Importance The pharmacokinetic parameters were highly variable among this group of dogs with MMVD . The variability was not associated with the dog's age, body weight or condition score, stage of heart disease, dose, serum creatinine, or alkaline phosphatase." @default.
• W4387214663 created "2023-10-01" @default.
• W4387214663 creator A5016943199 @default.
• W4387214663 creator A5077645210 @default.
• W4387214663 creator A5081139078 @default.
• W4387214663 creator A5088257004 @default.
• W4387214663 date "2023-09-30" @default.
• W4387214663 modified "2023-10-02" @default.
• W4387214663 title "Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease" @default.
• W4387214663 cites W1834130069 @default.
• W4387214663 cites W1875706817 @default.
• W4387214663 cites W1946619398 @default.
• W4387214663 cites W2002594730 @default.
• W4387214663 cites W2070740297 @default.
• W4387214663 cites W2117902834 @default.
• W4387214663 cites W2132162955 @default.
• W4387214663 cites W2171446417 @default.
• W4387214663 cites W2487166295 @default.
• W4387214663 cites W2508412301 @default.
• W4387214663 cites W2520403332 @default.
• W4387214663 cites W2525681105 @default.
• W4387214663 cites W2744457775 @default.
• W4387214663 cites W2773971449 @default.
• W4387214663 cites W2792870431 @default.
• W4387214663 cites W2891738248 @default.
• W4387214663 cites W2939525683 @default.
• W4387214663 cites W2995947619 @default.
• W4387214663 cites W3149525659 @default.
• W4387214663 cites W4295485340 @default.
• W4387214663 doi "https://doi.org/10.1111/jvim.16891" @default.
• W4387214663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37776546" @default.
• W4387214663 hasPublicationYear "2023" @default.
• W4387214663 type Work @default.
• W4387214663 citedByCount "0" @default.
• W4387214663 crossrefType "journal-article" @default.
• W4387214663 hasAuthorship W4387214663A5016943199 @default.
• W4387214663 hasAuthorship W4387214663A5077645210 @default.
• W4387214663 hasAuthorship W4387214663A5081139078 @default.
• W4387214663 hasAuthorship W4387214663A5088257004 @default.
• W4387214663 hasBestOaLocation W43872146631 @default.
• W4387214663 hasConcept C112705442 @default.
• W4387214663 hasConcept C126322002 @default.
• W4387214663 hasConcept C164705383 @default.
• W4387214663 hasConcept C2777477808 @default.
• W4387214663 hasConcept C2908647359 @default.
• W4387214663 hasConcept C71924100 @default.
• W4387214663 hasConcept C99454951 @default.
• W4387214663 hasConceptScore W4387214663C112705442 @default.
• W4387214663 hasConceptScore W4387214663C126322002 @default.
• W4387214663 hasConceptScore W4387214663C164705383 @default.
• W4387214663 hasConceptScore W4387214663C2777477808 @default.
• W4387214663 hasConceptScore W4387214663C2908647359 @default.
• W4387214663 hasConceptScore W4387214663C71924100 @default.
• W4387214663 hasConceptScore W4387214663C99454951 @default.
• W4387214663 hasLocation W43872146631 @default.
• W4387214663 hasLocation W43872146632 @default.
• W4387214663 hasOpenAccess W4387214663 @default.
• W4387214663 hasPrimaryLocation W43872146631 @default.
• W4387214663 hasRelatedWork W2002812539 @default.
• W4387214663 hasRelatedWork W2024826226 @default.
• W4387214663 hasRelatedWork W2074722739 @default.
• W4387214663 hasRelatedWork W2080913083 @default.
• W4387214663 hasRelatedWork W2151580563 @default.
• W4387214663 hasRelatedWork W2167270482 @default.
• W4387214663 hasRelatedWork W2413221923 @default.
• W4387214663 hasRelatedWork W2427668791 @default.
• W4387214663 hasRelatedWork W2793338951 @default.
• W4387214663 hasRelatedWork W1924049245 @default.
• W4387214663 isParatext "false" @default.
• W4387214663 isRetracted "false" @default.
• W4387214663 workType "article" @default.